Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022451 · ClinicalTrials.gov registry record · Phase 1
Tipifarnib in Treating Young Patients With Refractory Leukemia
A Phase 1 study of Leukemia, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Study locations
NCT00022451: Completed Phase 1 study of Leukemia, sponsored by National Institutes of Health Clinical Center (CC).
NCT00022451 is a Phase 1 study of Leukemia that has completed, run by National Institutes of Health Clinical Center (CC). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00022451, a Phase 1 study of Leukemia, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of tipifarnib in treating young patients who have refractory leukemia.
Conditions Studied
Interventions
- DRUG tipifarnib
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Children's Hospital Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Children's Hospital of Orange County - Orange
- UCSF Comprehensive Cancer Center - San Francisco
- Stanford Cancer Center at Stanford University Medical Center - Stanford
Georgia
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus - Atlanta
- MBCCOP-Medical College of Georgia Cancer Center - Augusta
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda
Massachusetts
- Floating Hospital for Children - Boston
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute - Boston
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- Shands Cancer Center at the University of Florida Health Science Center - Gainesville
Illinois
- Children's Memorial Hospital - Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
What the finished NCT00022451 record still lists
NCT00022451 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which tipifarnib is the first listed.
NCT00022451 names 20 study sites across 11 states, led by California, Georgia, Maryland.
Frequently Asked Questions
What is clinical trial NCT00022451 about?
NCT00022451 is a clinical study titled "Tipifarnib in Treating Young Patients With Refractory Leukemia". RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of tipifarnib in treating young patients who have refractory leukemia.
What is the current status of trial NCT00022451?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-06. Estimated completion is 2005-03.
What conditions does trial NCT00022451 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00022451?
The interventions under investigation include: tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00022451?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00022451 being conducted?
This trial has 20 study locations across Arkansas, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia